Physician profile
Jeffrey Richmond
NPI 1831414507
$424,167.72
in general payments reported to CMS, 2019-2025
35 companies · $108K in 2025
The $108K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,808 · 2020: $1,041 · 2021: $5,877 · 2022: $29K · 2023: $147K · 2024: $130K · 2025: $108K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $273K · Travel and Lodging: $38K · Consulting Fee: $34K · Honoraria: $26K · Food and Beverage: $14K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $273,495.00 |
| Travel and Lodging | $38,315.09 |
| Consulting Fee | $33,685.00 |
| Honoraria | $26,400.00 |
| Food and Beverage | $13,593.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $127,449.41 | 2019-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $108,099.76 | 2020-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $69,054.64 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $55,475.25 | 2023-2025 | Auvelity, Sunosi |
| Abbvie INC. | $33,073.41 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $13,211.11 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $6,915.31 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Corium, LLC | $4,677.57 | 2022-2025 | Azstarys, Azstarys |
| Neuronetics, INC. | $748.91 | 2019-2020 | |
| Lundbeck LLC | $664.17 | 2019-2025 | Rexulti |
| Janssen Scientific Affairs, LLC | $590.45 | 2019-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $534.90 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $516.23 | 2019-2025 | Fanapt |
| Alkermes, INC. | $480.18 | 2019-2025 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $464.99 | 2022-2024 | Qelbree |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $441.42 | 2019-2024 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $438.15 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $265.91 | 2019-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $187.66 | 2019-2023 | Jornay Pm |
| Allergan, INC. | $179.54 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $85.53 | 2019-2022 | |
| Adlon Therapeutics L.P. | $74.09 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $73.94 | 2019 | |
| Tris Pharma INC | $70.58 | 2022-2024 | Dyanavel Xr |
| Shire North American Group INC | $61.80 | 2019 | |
| Uswm, LLC | $59.61 | 2021 | |
| Noven Therapeutics, LLC | $58.17 | 2024 | Xelstrym, Secuado |
| Neos Therapeutics, Lp | $51.21 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.97 | 2023 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $24.24 | 2022 | |
| Biogen, INC. | $23.56 | 2024 | Zurzuvae |
| Sage Therapeutics, LLC | $22.04 | 2024 | |
| Alfasigma USA, INC. | $18.43 | 2021 | |
| Eisai INC. | $14.17 | 2022 | |
| Indivior INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Richmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.